Incubating new quality from the source·Opening up a new pharmaceutical ecology
From June 20 to 22, 2024, the 3rd Linping Biomedicine Source Innovation Conference concluded successfully in Linping, Hangzhou! Our company attended this conference as a conference participant. This conference is jointly sponsored by Zhejiang University School of Basic Medicine, Zhejiang University (Linping) Basic Medical Innovation Institute, Zhejiang Biomedical Society, Yangtze River Delta Biomedicine Collaborative Innovation Alliance, Hangzhou Linping District Biomedicine Association, Zhejiang University Science and Technology Park Co-organized by Linping Qizhen Medical Innovation Industry Base. At the same time, the Hangzhou Linping Economic and Technological Development Zone Management Committee, as a cooperative unit, provided strong support for the success of the conference.
The theme of the conference is "Incubating new quality from the source and initiating a new medical ecology". Deng Zixin, academician of the Chinese Academy of Sciences, Huang Xianhai, member of the Standing Committee of the Party Committee and Vice President of Zhejiang University, Jiang Shibo, academician of the American Academy of Microbiology and director of the Institute of Pathogen Microbiology of Fudan University, China Special invitation from the Chemical and Pharmaceutical Industry Association Zhang Ziran, vice president and director of the Medical Policy and Regulations Professional Committee, Wang Yangjie, second-level inspector of the Zhejiang Science and Technology Association, Chen Yan, director of the Comprehensive Service Center of Linping Economic and Technological Development Zone and director of the Entrepreneurship and Innovation Bureau (Talent Service Bureau), Zhejiang Science and Technology Association Party Committee of Science and Technology Societies of Technical Associations and Societies Deputy Secretary Wang Hui, Secretary of the School of Basic Medicine of Zhejiang University Lou Jianqing, Dean of the Institute of Basic Medical Innovation of Zhejiang University (Linping) Yang Wei, Director of the Regional Innovation Management Department of the Institute of Science and Technology of Zhejiang University Hu Zhenhua, Deputy Director of the School of Basic Medicine of Zhejiang University Dean Zhang Yan, Vice President of Zhejiang Provincial Equity Trading Center General Manager Xia Wenrong, Deputy General Manager of Zhejiang University Science and Technology Park Company Yao Wenhe, President of Linping District Biomedical Association, Chairman and General Manager of Baicheng Pharmaceutical Lou Jinfang, Chairman of Kanglisheng Pharmaceutical Group Cheng Gang, etc. attended the event. Hundreds of government officials Authoritative experts from various fields including industry, academia, research, medicine and capital participated.
Huang Xianhai, member of the Standing Committee of the Party Committee and Vice President of Zhejiang University, delivered a welcome speech for the conference. He pointed out that the biopharmaceutical industry, as a strategic emerging industry, is of great significance. Zhejiang University adheres to the school motto of “Seeking Truth and Innovation” and strives to play a leading and exemplary role. Since its establishment, the Zhejiang University (Linping) Institute of Basic Medical Innovation has achieved results in many aspects. Currently, the global pharmaceutical and health industry is facing many changes and challenges. This conference aims to build a communication platform, promote the deep integration of scientific research and industry, provide new ideas and solutions for solving major problems in the pharmaceutical field, promote the birth of more original results, and promote industry-university-research. Deep integration to benefit people’s health.
Chen Yan , director of the Comprehensive Service Center of Linping Economic and Technological Development Zone and director of the Entrepreneurship and Innovation Bureau (Talent Service Bureau), said in his speech that Linping has a long history and profound heritage. After the establishment of the zone, it has promoted multiple industries and its GDP will exceed 100 billion in 2023. In recent years, Linping has set the goal of building an 80 billion life and health industry cluster, accelerating innovative resources and optimizing the industrial ecology. This conference is timely and of great significance. It is not only a summary and display of past achievements, but also an exploration and planning of future directions. Linping will always adhere to the innovation-driven development strategy and is committed to building a biomedical innovation highland.
In his speech, Wang Yangjie, the second-level inspector of the Zhejiang Association for Science and Technology, said that biomedicine is a strategic emerging industry in Zhejiang, and source innovation is crucial. In November 2023, the Provincial Science and Technology Association and the Chinese Pharmaceutical Association cooperated to promote the construction of Hangzhou's "China Medical Port", and Linping achieved remarkable results. As a provincial society, Zhejiang Biomedical Society actively builds a communication bridge between academia and industry, and promotes the accelerated gathering of innovative elements in Linping District. The Provincial Science and Technology Cooperation serves as the bridge and link between the Provincial Committee and the Provincial Government and scientific and technological workers. It will further strengthen the contact and cooperation with academic organizations and scientific and technological workers in the biomedical field to better assist the development of the province's biomedical industry.
Also held at the conference were the strategic cooperation signings between Zhejiang University (Linping) Institute of Basic Medical Innovation and CITIC Medical Fund, as well as the signing of cooperation and co-construction of a proof-of-concept center between the institute and Hangzhou Baicheng Pharmaceutical Technology Co., Ltd.
At the meeting, academicians and experts from all walks of life shared their insights on source innovation through keynote reports, high-end dialogues, roundtable interactions and other links.
The first chapter is themed "Source Innovation Empowers a New Pharmaceutical Ecosystem". Deng Zixin, academician of the Chinese Academy of Sciences, Jiang Shibo, director of the Institute of Pathogen Microbiology of Fudan University, and specially invited vice president of the China Chemical and Pharmaceutical Industry Association and director of the Medical Policy and Regulations Professional Committee Zhang Ziran delivered keynote speeches on the topics of "Synthetic Biology Drives Biological Design and Industrial Innovation", "The Development Prospects of Innovative Peptide Drugs" and "Encouraging the Development of Innovative Drugs throughout the Industry Chain"; Yang Wei, Dean of the Institute, hosted the high-end dialogue ,dialogue From the perspectives of industrial development, institutional environment, investment returns, and intellectual property protection, the topic of "accelerating original innovation and achieving high-quality development" was discussed in depth. Original innovation is the core starting point for generating new productivity and leading high-quality development. Accelerating original innovation requires the joint efforts of the whole society, including the active participation of governments, enterprises, academia and the public. This high-end dialogue is not only a profound understanding of the importance of original innovation, but also a useful exploration of future innovation paths.
The second chapter, with the theme of "Frontier Science and Technology Promoting Innovation and Development", was hosted by Zhang Yan, Vice Dean of the School of Basic Medicine of Zhejiang University. Shao Liming, Distinguished Professor of the Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Li Ping, Deputy General Manager of Guangzhou Zhiyi Biotechnology Co., Ltd., Zhang Jiyue, founder and CEO of Orui Pharmaceuticals, Wan Xiaobo, CEO of Conmedison, and Aimeifei Biomedicine Technology Co., Ltd. Chairman/CEO Fan Guohuang, Xu Jun, Director of the Drug Molecular Design Research Center of Sun Yat-sen University, and Chen Bingliang, Vice President of Innovent Biopharmaceuticals, discussed "Using Cutting-edge Technology to Address Challenges and Opportunities Facing Innovative Drugs" and "Development of Innovative Living Biopharmaceuticals Based on Bacteroides fragilis" ” and other topics were reported and shared. The guests also held a roundtable dialogue with the theme of "Challenges and Opportunities in the Discovery of New Drugs Empowered by Cutting-edge Technology" to explore how to break through innovative drugs in the era of rapid development of cutting-edge technologies.
The third chapter, "Construction of Source Innovation and Transformation Ecosystem" continued brilliantly, hosted by Zhang Honghe, Vice President of the Institute of Basic Medical Innovation of Zhejiang University (Linping). Cheng Zeneng, professor at the School of Pharmacy at Central South University, founder and chief scientist of Huize Pharmaceuticals, Hua Ye, chairman of Yehui Pharmaceuticals, Li Qi, director of the Department of Oncology at the First People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Cao Yueqiong, chairman of Genegene, Baicheng Pharmaceutical New Drugs Wang Jianghai, general manager of the Discovery Evaluation Center, shared his experience based on his own professional research and industrial experience. The third article ended with a roundtable interaction on "Clinical Needs, Source of Innovation: Exploring a New Future of Medicine". "Unmet clinical needs" is an eternal topic in pharmaceutical innovation and research and development. The guests at the meeting conducted in-depth exchanges around this theme and inspired Participants’ endless thoughts on the combination of innovation and clinical needs.
The fourth chapter, "Capital Empowerment to Pioneer Innovation and New Heights," concluded the conference and was hosted by Li Dawei, deputy director of the Institute of Basic Medical Innovation of Zhejiang University (Linping). Liu Luying, general manager of the Biomedicine Specialty Board Operations Center of Shanghai Technology Exchange, Mao Hua, partner and managing director of Frost & Sullivan Life Sciences, and Yang Xicheng, pharmaceutical industry analyst at Industrial Securities and leader of the innovative drug team, made a comprehensive analysis from a capital perspective The trends and challenges of biomedical source innovation are discussed.
This conference will last for two and a half days. It will comprehensively analyze the current trends and challenges of domestic source innovation, and discuss in-depth cooperation solutions. It is hoped that through this conference, we can create a communication platform for biomedicine source innovation and further lead the new trend of biomedicine innovation in China.